Company news

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) news

Every Arrowhead Pharmaceuticals, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) news

Press releases — page 2

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement

Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences

Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics

Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results

Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi

Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics

Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results

Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences

Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results

Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results

Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy

Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases

Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)

Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity

Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results

Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences

Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results

Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs

Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran

Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results

Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences

Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran

Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies

Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results

Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street

Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results

Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial

Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE

Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences

Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia

Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia